Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-23
2011-08-23
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S174100, C424S130100
Reexamination Certificate
active
08003105
ABSTRACT:
The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing combination therapy selected from R-ICE and R-DHAP. The treatment method of the present invention is useful for the treatment for all solid tumors and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer and the like. Particularly, they are expected as therapeutic agents for tumor types which show resistance against existing anticancer agents.
REFERENCES:
patent: 6335194 (2002-01-01), Bennett et al.
patent: 6734203 (2004-05-01), Matsuhisa et al.
patent: 2003/0114508 (2003-06-01), Matsuhisa et al.
patent: 2005/0119217 (2005-06-01), LaCasse et al.
patent: 2006/0223831 (2006-10-01), Kinoyama et al.
patent: 2006/0257401 (2006-11-01), Stassi et al.
patent: 2003128548 (2003-05-01), None
patent: 2003/521913 (2003-07-01), None
Nadia Zaffaroni et al., “Survivin as a target for new anticancer interventions”, J. Cell. Mol. Med., 2005, 9(2):360-372.
YJ Lian et al., “Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere”, Zhonghua Wei Chang Wai Ke Za Zhi (Chinese Journal of Gastrointestinal Surgery), 2005, 8(5):455-458.
Susanne Fuessel et al., “Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA”, Cancer Letters, 2006, 232:243-254.
Bing Z. Carter et al., “Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells”, Blood, 2006, 107(4):1555-1563.
Mehdi Mesri et al., “Cancer gene therapy using a survivin mutant adenovirus”, The Journal of Clinical Investigation, 2001, 108(7):981-990.
Norihiro Hayashi et al., “Adenoviral Infection of Survivin Antisense Sensitizes Prostate Cancer Cells to Etoposide In Vivo”, The Prostate, 2005, 65:10-19.
Min Zhang et al., “Adenovirus-Mediated Inhibition of Survivin Expression Sensitizes Human Prostate Cancer Cells to Paclitaxel In Vitro and In Vivo”, The Prostate, 2005, 64:293-302.
Takahito Nakahara et al., “YM155, a Novel Survivin Suppressant, Induced Downregulation of Survivin and Potent Antitumor Activities in Experimental Human Prostate Tumor Xenograft Models”, Proceedings AACR-NCI-EORTC, 2005, Abstract No. B203.
Takahito Nakahara et al., “Tumor regression induced by YM155, a novel, small molecule survivin suppressant, in experimental human lung tumor models”, Proceedings American Association Cancer Research, 2006, vol. 47, Abstract No. 5671.
A.W. Tolcher et al., “YM155, A Novel Survivin Supressant, Demonstrates Anti-tumor Activity in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma”, Annals of Oncology, 2006, 17(Suppl. 3): 23, Abstract No. O.403.
A.W. Tolcher et al., “A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors”, Journal of Clinical Oncology, 2006, 24(18S):Abstract No. 3014.
John D. Hainsworth et al., “Paclitaxel, Carboplatin, and Extended Schedule Etoposide in the Treatment of Small Cell Lung Carcinoma”, Cancer, 1996, 77(12):2458-2463.
Sergio Ricci et al., “A Randomized Study Comparing Two Different Schedules of Administration of Cisplatin in Combination with Gemcitabine in Advanced Nonsmall Cell Lung Carcinoma”, Cancer, 2000, 89(8):1714-1719.
H. Hagberg et al., “Randomised phase III study of R-ICE versus R-DHAP in relapses patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study”, Annals of Oncology, 2006, 17(Suppl. 4):iv31-iv32.
Tarun Kewalramani et al., “Rituximad and ICE as second-line therapy before autologus stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma”, Blood, 2004, 103(10):3684-3688.
Regis Peffault De LaTour et al., “Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma,” Leukemia & Lymphoma, 2007, 48(5):897-904.
Daniel S. O'Connor et al., “A p34cdc2survival checkpoint in cancer”, Cancer Cell, 2002, 2(1):43-54.
Takahito Nakahara et al., “YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts”, Cancer Res., 2007, 67(17):8014-8021.
Kazuhiko Nakagawa, “Report of Shared Scientific Research Subsidized by the Ministry of Health and Labor (for Third General Anti-Cancer Strategic Research Project)”, 2006, pp. 29-30.
Tsuneo Sasaki, Igaku no ayumi (Medical Progress), 1993, 164(5):251-254.
Tadato Nakahara et al., “Article from the General Annual Academic Assembly of Nippon Cancer Association”, 2006, 65;495-496.
Aya Kita et al., “Article from the General Annual Academic Assembly of Nippon Cancer Association”, 2006, 65:496.
Kentaro Yamanaka et al., “Article from the General Annual Academic Assembly of Nippon Cancer Association”, 2006, 65:496.
Yamamoto, T., “Fundamental Studies for Gene Therapy using Survivin as a Target”, Jpn. J. Cancer Chemother., vol. 30, No. 11, pp. 1805-1808, Oct. 31, 2003.
Shoji, D., “Chemotherapy-induced anemia in lymphoma patients”, Hematology & Oncology, vol. 52, No. 2, pp. 216-225, Feb. 28, 2006.
Japanese Examination Report dated Jan. 6, 2011, as issued in Japanese Patent Application No. 2008/552,180.
Kita Aya
Koutoku Hiroshi
Nakahara Takahito
Yamanaka Kentaro
Astellas Pharma Inc.
Huff Sheela J
Sughrue & Mion, PLLC
LandOfFree
Method of treating cancer by co-administration of anticancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cancer by co-administration of anticancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cancer by co-administration of anticancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2785329